Abstract: A compound having the formula Ir(LA)x(LB)y(LC)z is disclosed wherein ligand LA has a structure of Formula I, ligand LB has a structure of Formula II, and ligand LC is a bidentate ligand. R1, R2, R3, R4, RD, and RE do not include an electron-withdrawing group; if R1 has an alkyl group with four and more carbon atoms, then RA1 is not neopentyl; and R1 is not a trialkylsilyl or trilalkylgermyl group. Further, at least one is true: at least one RB or RC comprises heteroaryl, wherein the heteroaryl does not comprise the structure, two RB or RC groups are joined to form a fused carbocyclic or heterocyclic ring; or X8 is N, or C with RB attached thereto being D, or CD3, and RA1 is a secondary or tertiary alkyl, cycloalkyl, heteroaryl, or ortho-substituted aryl. Compositions, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound including a first ligand LA of Formula I, is described. In Formula I, each of X1 to X9 is independently C or N; one of Z1 and Z2 is C and the other is N; each of K1 and K2 is independently a direct bond, O, or S; at least one of K1 and K2 is a direct bond; at least one RB is not hydrogen; R3 is selected from alkyl, heteroalkyl, cycloalkyl, and heterocycloalkyl; LA is coordinated to a metal M; at least one of the following is true: (i) at least one RB comprises a 5- or 6-membered, (ii) two adjacent RB are joined to form a fused 5- or 6-membered ring, or (iii) RB comprises a carbocyclic or heterocyclic ring substituted with at least one electron withdrawing group. Devices, consumer products, and formulations including the compound are also described.

Abstract: Provided are organometallic compounds. Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

Abstract: Provided are organometallic compounds having a structure of Formula I: Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

Abstract: A compound including a first ligand LA of Formula I, is disclosed. In Formula I, ring B is a 5- or 6-membered ring; X1, X2, and X3 are each CRA or N; R is a 5- or 6-membered carbocyclic or heterocyclic ring, which can be further fused or substituted; and (1) when ring B is an unfused 6-membered ring, X1 and X2 are N, and X3 is C; and (2) when ring B is a fused 6-membered ring, ring B has the structure of Formula II, In this structure, the wavy line indicates the point of connection to ring A; Q1 to Q6 are each C or N; and, when proviso (2) applies, (I) at least one of X1, X2, and X3 is N; or (II) R is two or more fused or unfused 5- or 6-membered carbocyclic or heterocyclic rings, or (III) at least ring A or R is substituted with a partially or fully deuterated alkyl or partially or fully deuterated cycloalkyl group.

Abstract: Provided are organometallic compounds having Formula I: Also provided are formulations including these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

Abstract: A compound having a first ligand LA of structure of Formula I, is provided. In the structure, each of moiety A and moiety C is a monocyclic ring or a polycyclic fused ring system; moiety B is a polycyclic fused ring system including at least four fused rings; each of Z1 to Z3 is C or N; L is a direct bond or a linking group; K is a direct bond or a linking group; each R, R?, R?, R?, RA, RB, and RC is hydrogen or a General Substituent defined herein; and LA is coordinated to a metal M. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A composition of materials including a first compound having a structure according to Formula I

Abstract: A compound including a first ligand LA of Formula I, is described. In Formula I, each of X1 to X9 is independently C or N; one of Z1 and Z2 is C and the other is N; each of K1 and K2 is independently a direct bond, O, or S; at least one of K1 and K2 is a direct bond; at least one RB is not hydrogen; R3 is selected from alkyl, heteroalkyl, cycloalkyl, and heterocycloalkyl; LA is coordinated to a metal M; at least one of the following is true: (i) at least one RB comprises a 5- or 6-membered, (ii) two adjacent RB are joined to form a fused 5- or 6-membered ring, or (iii) RB comprises a carbocyclic or heterocyclic ring substituted with at least one electron withdrawing group. Devices, consumer products, and formulations including the compound are also described.

Abstract: A compound is provided that has a formula Ir(LA)x(LB)y(LC)z, where each of x and y is independently 1 or 2, z is 0 or 1, and x+y+z=3; ligand LA comprises a structure of Formula I, ligand LB comprises a structure of Formula II, and ligand LC is a bidentate ligand. In Formulas I and II, each of X1 to X14 is C or N; Y is a linking group; each R, R?, R*, R1, R2, R3, RA, RB, RC, and RE is a hydrogen or a variety of substituent defined herein; and R4 comprises a tertiary or secondary alkyl group and can also include one or more General Substituents defined herein. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound having a structure of Formula I In Formula I, M is Pd or Pt; each of X1 to X12 is independently C or N; ring A is a 5-membered or 6-membered ring; K1 and K2 are selected from a direct bond, O, S, and NR; L1 is an organic linker; Y1 is selected from O, S, BR, PR, Se and NRY; each R, RY, RA, RB, RC, and RD is hydrogen or a substituent; and any two substituents can be joined or fused to form a ring. Further provided are OLEDs and related consumer products that utilize these compounds.

Abstract: A compound having the formula: is disclosed. The compound is useful as emitters in OLEDs.

Abstract: A compound having a first ligand LA having the Formula: Formula I is disclosed, wherein rings A is a 5- or 6-membered carbocyclic or heterocyclic ring; wherein RA and RB each independently represent mono to the possible maximum number of substitution, or no substitution; wherein Z1 is carbon or nitrogen; wherein each RA and RB is independently selected from the group consisting of hydrogen, deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; wherein any two substituents are optionally joined or fused into a ring; wherein X1 to X4 each independently represent a carbon or nitrogen; wherein at least one of X1 to X4 is nitrogen; wherein the ligand LA is coordinated to a metal M; wherein the metal M can be coordinated to other ligands; and wherein the ligand LA is optionally l

Abstract: A compound having a first ligand LA comprising a structure of Formula I, is provided. In the compound, each of moiety A and moiety B is a monocyclic ring or a polycyclic fused ring system; at least one RA or RB has a structure of Formula II, wherein the dashed line represents a bond to moiety A or moiety B, respectively; moiety D is a polycyclic fused ring system; each of Z1 to Z4 and X1 to X5 is C or N; L is a direct bond or a linking group; Y is a linking group; each of K1 and K2 is a direct bond or a linking group; and the dashed lines of Formula I are coordinated to a metal M. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound of Formula Ir(LA)x(LB)y(LC)z is provided, where LA comprises a structure of Formula I, and each of LB and LC is a bidentate ligand. In the compound, moiety A is a 5-membered or 6-membered carbocyclic or heterocyclic ring; moiety B is a polycyclic fused ring system containing at least five rings; at least one RA comprises a structure of Formula II, each of X1 to X5, Z1 and Z2 is C or N; K is a direct bond or a linker, Y is a linking group; L is a direct bond or a linking group; and each R substituent is hydrogen or a General Substituent defined herein. Formulations, OLEDs, and consumer products containing the same are also provided.

Abstract: Iridium complexes comprising three different bidentate ligands and their use in OLEDs to enhance the device efficiency and lifetime are disclosed. The complexes have a structure of the formula Ir(LA)(LB)(LC), where ligand LA is selected from a variety of structures, ligand LB has the structure and LC has the structure In these structures rings A, B, C, and D are each independently a 5 or 6-membered carbocyclic or heterocyclic ring; R1, R2, R3, RA, RB, RC, and RD can be any of a variety of substituents, and Z1 and Z2 are each independently C or N.

Abstract: A compound is disclosed that has a metal coordination complex structure having at least two ligands coordinated to the metal; wherein the compound has a first substituent R1 at one of the ligands' periphery; wherein a first distance is defined as the distance between the metal and one of the atoms in R1 where that atom is the farthest away from the metal among the atoms in R1; wherein the first distance is also longer than any other atom-to-metal distance between the metal and any other atoms in the compound; and wherein when a sphere having a radius r is defined whose center is at the metal and the radius r is the smallest radius that will allow the sphere to enclose all atoms in the compound that are not part of R1, the first distance is longer than the radius r by at least 2.9 A.

Abstract: New organometallic complexes having bis- or tris- heteroleptic ligands and large aspect ratio in one direction and their use in OLEDs to enhance the efficiency is disclosed. Such compounds can have a structure of Formula III, where rings A, B, C, and D are ring; L1 and L3 each a direct bond or a linking group; n1 and n2 are 0 or 1; if n1 or n2 is 1, then L2 or L4 is a direct bond or a linking group, and if n1 or n2 is 0, L2 or L4 is not present; Q1, Q2, Q3 and Q4 are a direct bond or oxygen; ring A is trans to ring D, ring B is trans to ring C in a square-planar coordination configuration; M2 is Pt, and the compound comprises at least one Pt-carbene bond.

Abstract: A compound having a first ligand LA with a structure of Formula I, where two consecutive ones of X1 to X8 are C and are joined to a structure of Formula II, is provided. In Formula I, moiety A is a monocyclic ring or a polycyclic fused ring system; each of Z1 to Z2 and X1 to X12 is C or N; each of Y1 and Y2 is a linker; K is a direct bond or a linker; each substituent is hydrogen or a General Substituent defined herein; and LA is coordinated to a metal M. Also provided is a compound having a formula Ir(LA*)x(LB*)y(LC*)z as defined herein. Formulations, OLEDs, and consumer products containing these compounds are further provided.

Abstract: A compound having the formula Ir(LA)n(LB)3-m, having the structure of Formula I is provided. In the structure of Formula I, each of A1 through A8 is independently carbon or nitrogen; at least one of A1 through A8 is nitrogen; ring B is bonded to ring A through a C—C bond; the iridium is bonded to ring A through an Ir—C bond; X is O, S, or Se; each of R1 through R5 are independently selected from a variety of substituents, which may be linked for form a ring; n is an integer from 1 to 3; and at least one R2 adjacent to ring C is not hydrogen. Formulations and devices, such as OLEDs, that include the first compound are also provided.